---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-026409"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:52:51.981149+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics raises $7.8M in registered direct offering and amends prior warrants

## Summary
- Sold 2,480,294 common shares and pre-funded warrants for 2,020,491 shares at combined $1.739/unit, plus accompanying warrants.
- Gross proceeds ~$7.8M; placement agent fees 6% cash plus 180,031 warrants at $2.0175.
- Warrant amendment reduces exercise price to $1.614 on 1,385,083 prior warrants and extends term to 5 years; investor paid ~$173k.
- Proceeds used for working capital and general corporate purposes.
- Offering closed March 11, 2026; common stock trades on Nasdaq under BTAI.

## SEC filing metadata
- accession: 0001104659-26-026409
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465926026409/0001104659-26-026409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465926026409/tm268136d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-026409
- JSON: https://secwatch.observer/filing/0001104659-26-026409.json
- Plain text: https://secwatch.observer/filing/0001104659-26-026409.txt

## Key facts
- Material Agreements
  BioXcel Therapeutics, Inc. entered into Purchase Agreement with the Purchaser valued at approximately $7.8 million (effective 2026-03-10).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Purchaser
  - Value: approximately $7.8 million
  - Effective: 2026-03-10
  source text: On March 10, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchaser named therein
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465926026409/0001104659-26-026409-index.htm
- Material Agreements
  BioXcel Therapeutics, Inc. amended Warrant Amendment Agreement with the Purchaser valued at approximately $173,135 (effective 2026-03-10).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: the Purchaser
  - Value: approximately $173,135
  - Effective: 2026-03-10
  source text: In connection with the Offering, pursuant to the terms of a Warrant Amendment Agreement, dated as of March 10, 2026 (the “Warrant Amendment Agreement”), the exercise price of certain outstanding warrants issued on March 27, 2024 and November 25, 2024 to purchase up to an aggregate of 1,385,083 shares of Common Stock held by the Purchaser was reduced to $1.614 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465926026409/0001104659-26-026409-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.